Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2008 Nov;79(5):678-84.

Phase I clinical evaluation of rDEN4Delta30-200,201: a live attenuated dengue 4 vaccine candidate designed for decreased hepatotoxicity

Affiliations
Clinical Trial

Phase I clinical evaluation of rDEN4Delta30-200,201: a live attenuated dengue 4 vaccine candidate designed for decreased hepatotoxicity

Julie H McArthur et al. Am J Trop Med Hyg. 2008 Nov.

Abstract

The rDEN4Delta30-200,201 is a live attenuated DENV-4 vaccine candidate specifically designed to further attenuate the rDEN4Delta30 parent virus. In the present study, 28 healthy adult volunteers were randomized to receive either 10(5) plaque-forming unit (PFU) of vaccine (20) or placebo (8) as a single subcutaneous injection. Volunteers were evaluated for safety every other day for 16 days. Serum neutralizing antibody titer against DEN4 was determined at study day 28, 42, and 180. The vaccine infected all vaccinees and was well tolerated without inducing alanine aminotransferase (ALT) elevations. Although virus was not recovered from the serum of any vaccinee, moderate levels of neutralizing antibody were induced in all volunteers. Thus the restricted replication of rDEN4Delta30-200,201 previously documented in animal models was confirmed in humans. The rDEN4Delta30-200,201 is a promising candidate and can be considered for inclusion in a tetravalent dengue virus (DENV) vaccine.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Frequency of selected clinical signs from volunteers receiving 105 plaque-forming unit (PFU) of rDEN4Δ30-200,201 vaccine candidate, 105 PFU of rDEN4Δ30 vaccine candidate, or placebo. The frequency of viremia, rash, and serum alanine aminotransferase (ALT) elevation were significantly lower among recipients of the rDEN4Δ30-200,201 vaccine compared with recipients of the rDEN4Δ30 vaccine (*, P = 0.0001; **, P = 0.02; ***, P = 0.05).
Figure 2
Figure 2
Direct comparison of the PRNT60 at day 42 of volunteers vaccinated with rDEN4Δ30-200,201 or rDEN4Δ30. Vaccinees in each trial received 105 plaque-forming unit (PFU) of vaccine as a single subcutaneous dose. Day 42 serum samples collected from vaccinees enrolled in this rDEN4Δ30-200,201 clinical trial and day 42 serum samples retained from vaccinees enrolled in the previous rDEN4Δ30 clinical trial were evaluated in the same PRNT assay. The geometric mean titer is shown and standard deviation levels are indicated.

Similar articles

Cited by

References

    1. Suaya JA, Shepard DS, Beatty ME. Scientific Working Group on Dengue—2006 Report. Geneva: WHO; 2006. Dengue: Burden of Disease and Costs of Illness; pp. 35–49.
    1. Mathers CD, Ezzati M, Lopez AD. Measuring the burden of neglected tropical diseases: the global burden of disease framework. PLoS Negl Trop Dis. 2007;1:e114. - PMC - PubMed
    1. World Health Organization. Dengue Haemorrhagic Fever: Diagnosis, Treatment, Prevention and Control. Geneva: WHO; 1997.
    1. Sabin A. Research on dengue during World War II. Am J Trop Med Hyg. 1952;1:30–50. - PubMed
    1. Okuno Y, Fukunaga T, Tadano M, Fukai K, Ikeda T, Sekii K, Ariyoshi H. Serological studies on volunteers inoculated experimentally with a dengue virus strain in 1943. Biken J. 1983;26:161–163. - PubMed

Publication types

LinkOut - more resources